Earlier results suggest an involvement of COX-2 in the control of tumor-dependent angiogenesis and growth in certain pancreatic cancers and provide the rationale for inhibition of the COX pathway as an effective therapeutic approach for pancreatic tumors [3, 9]. Here, PTGS2 is linked to familial pancreatic carcinoma.